Literature DB >> 34863953

Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease.

Pooja Patel1, Jillian C Bensko2, Neil Bhattacharyya3, Tanya M Laidlaw4, Kathleen M Buchheit5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34863953      PMCID： PMC8882131          DOI： 10.1016/j.anai.2021.11.020

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN： 1081-1206            Impact factor:   6.347


× No keyword cloud information.
  10 in total

1.  Aspirin-Exacerbated Respiratory Disease--New Prime Suspects.

Authors:  Tanya M Laidlaw; Joshua A Boyce
Journal:  N Engl J Med       Date:  2016-02-04       Impact factor: 91.245

2.  Medical and surgical considerations in patients with Samter's triad.

Authors:  K Christopher McMains; Stilianos E Kountakis
Journal:  Am J Rhinol       Date:  2006 Nov-Dec

3.  Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper.

Authors:  Marek L Kowalski; Ioana Agache; Sevim Bavbek; Arzu Bakirtas; Miguel Blanca; Grażyna Bochenek; Matteo Bonini; Enrico Heffler; Ludger Klimek; Tanya M Laidlaw; Joaquim Mullol; Ewa Niżankowska-Mogilnicka; Hae-Sim Park; Marek Sanak; Mario Sanchez-Borges; Silvia Sanchez-Garcia; Glenis Scadding; Masami Taniguchi; Maria J Torres; Andrew A White; Aleksandra Wardzyńska
Journal:  Allergy       Date:  2018-10-02       Impact factor: 13.146

4.  Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD.

Authors:  Tanya M Laidlaw; Joaquim Mullol; Chunpeng Fan; Donghui Zhang; Nikhil Amin; Asif Khan; Jingdong Chao; Leda P Mannent
Journal:  J Allergy Clin Immunol Pract       Date:  2019-04-04

5.  Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease.

Authors:  M Pilar Berges-Gimeno; Ronald A Simon; Donald D Stevenson
Journal:  J Allergy Clin Immunol       Date:  2003-01       Impact factor: 10.793

6.  Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.

Authors:  Claus Bachert; Joseph K Han; Martin Desrosiers; Peter W Hellings; Nikhil Amin; Stella E Lee; Joaquim Mullol; Leon S Greos; John V Bosso; Tanya M Laidlaw; Anders U Cervin; Jorge F Maspero; Claire Hopkins; Heidi Olze; G Walter Canonica; Pierluigi Paggiaro; Seong H Cho; Wytske J Fokkens; Shigeharu Fujieda; Mei Zhang; Xin Lu; Chunpeng Fan; Steven Draikiwicz; Siddhesh A Kamat; Asif Khan; Gianluca Pirozzi; Naimish Patel; Neil M H Graham; Marcella Ruddy; Heribert Staudinger; David Weinreich; Neil Stahl; George D Yancopoulos; Leda P Mannent
Journal:  Lancet       Date:  2019-09-19       Impact factor: 79.321

7.  Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial.

Authors:  Claus Bachert; Leda Mannent; Robert M Naclerio; Joaquim Mullol; Berrylin J Ferguson; Philippe Gevaert; Peter Hellings; Lixia Jiao; Lin Wang; Robert R Evans; Gianluca Pirozzi; Neil M Graham; Brian Swanson; Jennifer D Hamilton; Allen Radin; Namita A Gandhi; Neil Stahl; George D Yancopoulos; E Rand Sutherland
Journal:  JAMA       Date:  2016-02-02       Impact factor: 56.272

Review 8.  The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.

Authors:  Whitney W Stevens; Elina Jerschow; Alan P Baptist; Larry Borish; John V Bosso; Kathleen M Buchheit; Katherine N Cahill; Paloma Campo; Seong H Cho; Anjeni Keswani; Joshua M Levy; Anil Nanda; Tanya M Laidlaw; Andrew A White
Journal:  J Allergy Clin Immunol       Date:  2020-12-09       Impact factor: 10.793

9.  Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease.

Authors:  Kathleen M Buchheit; Tanya M Laidlaw; Joshua M Levy
Journal:  J Allergy Clin Immunol       Date:  2021-06-23       Impact factor: 14.290

10.  Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps.

Authors:  Neil Bhattacharyya; Sara Villeneuve; Vijay N Joish; Caroline Amand; Leda Mannent; Nikhil Amin; Paul Rowe; Jaman Maroni; Laurent Eckert; Tony Yang; Asif Khan
Journal:  Laryngoscope       Date:  2019-02-05       Impact factor: 3.325
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.